As expected, TF increased sharply in vehicle‐treated mice, particularly after Day 7, while CD19‐CAR‐DNTs suppressed tumor burden in a dose‐dependent manner (Figure 6f) and significantly prolonged the survival compared with vehicle control (Figure 6g). This evidence concerns the gene CD19 and neoplasm.